Initiation of Clinical Trials, Completed Acquisitions, Financial Results, and Earnings Release Schedules - Analyst Notes on Cell Therapeutics, Intrexon, Chimerix, Receptos, and Revance Therapeutics

NEW YORK, March 18, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Cell Therapeutics, Inc. (NASDAQ: CTIC), Intrexon Corporation (NYSE: XON), Chimerix, Inc. (NASDAQ: CMRX), Receptos, Inc. (NASDAQ: RCPT), andRevance Therapeutics, Inc. (NASDAQ: RVNC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Cell  Therapeutics,  Inc.  Analyst  Notes

On March 3, 2014, Cell Therapeutics, Inc. (CTI) announced the initiation of a Phase 3 clinical trial, PERSIST-2, evaluating pacritinib. Pacritinib is a novel investigational JAK2/FLT3 inhibitor, in patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter (uL). "With the initiation of the PERSIST-2 trial, we believe that the registration program for pacritinib is on track for a potential NDA submission in the latter part of 2015," said James A. Bianco, MD, President and CEO of CTI. "We have seen meaningful clinical benefits and good tolerability with pacritinib in myelofibrosis patients in Phase 2 trials without apparent drug-related thrombocytopenia or anemia. As such, we have had strong interest in site participation for this trial and will work diligently to activate these sites over the next several months." The trial is expected to enroll up to 300 patients in North America, Europe, Australia and New Zealand within 12 to 14 months. The full analyst notes on Cell Therapeutics, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03182014/CTIC/report.pdf

Intrexon  Corporation  Analyst  Notes

On March 7, 2014, Intrexon Corp. (Intrexon) announced that it has completed the acquisition of Medistem, Inc., a pioneer in the development of Endometrial Regenerative Cells. Under the terms of the agreement, Medistem stockholders will receive in exchange for each share of Medistem common stock $0.27 in cash and $1.08 worth of Intrexon common stock, or approximately 0.03920 shares. This is based on the 20-day volume-weighted average price of Intrexon's common stock immediately prior to closing, subject to adjustment pursuant to the terms of the merger agreement. The full analyst notes on Intrexon Corporation are available to download free of charge at:

http://www.AnalystsReview.com/03182014/XON/report.pdf

Chimerix,  Inc.  Analyst  Notes

On March 7, 2014, Chimerix Inc. (Chimerix) reported its Q4 2013 and full-year 2013 financial results. For the quarter, the Company reported a net loss of $8.2 million or $0.31 per basic and diluted share,compared to a net loss of $4.3 million or $3.90 per basic and diluted share in Q4 2012. Revenues totaled $879,000, compared to $3.6 million in Q4 2012. For full-year 2013, net loss was $36.4 million or $3.65 per basic and diluted share, compared to net loss of $4.4 million or $5.75 per basic and diluted share in 2012. Revenues were $4.4 million, compared to $33.7 million in 2012. The decrease in revenues were attributable to a decrease in reimbursable expenses associated with Chimerix's ongoing contract with BARDA in 2013, and the receipt of an upfront license payment related to Chimerix's collaboration and license arrangement with Merck in 2012. The full analyst notes on Chimerix, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03182014/CMRX/report.pdf

Receptos,  Inc.  Analyst  Notes

On March 5, 2014, Receptos, Inc. (Receptos) reported its Q4 2013 and full-year 2013 (period ended December 31, 2013) financial results. For the quarter, the Company reported net loss of $15.2 million, or $0.86 per common share, compared to a net loss of $4.5 million, or $3.08 per common share, in Q4 2012. Total revenues were $773,000, compared to $3.8 million in Q4 2012. Revenue during these periods consisted primarily of amortization of up-front fees and milestone payments, and development funding received from our collaborative arrangements. Fiscal year 2013 net loss was as $50.4 million, or $4.23 per common share, compared to a net loss of $17.7 million, or $13.73 per common share, in 2012. Total revenues were $4.6 million compared to $8.6 million in 2012. The full analyst notes on Receptos, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03182014/RCPT/report.pdf

Revance  Therapeutics,  Inc.  Analyst  Notes

On March 12, 2014, Revance Therapeutics, Inc. (Revance) announced the schedule of its earnings release and conference call. The Company will report its Q4 2013 and full-year 2013 financial results on March 26, 2014, Wednesday, after the close of market. The Company's management will also host a conference call and live internet webcast on the same day at 1:30 p.m. PT or 4:30 p.m. ET to discuss the results as well as provide business updates. The webcast will be available in the Investor Relations section on the Company's website for 30 days following the completion of the call. The full analyst notes on Revance Therapeutics, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03182014/RVNC/report.pdf

About Analysts Review

We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

=============

EDITOR  NOTES:

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For  any  urgent  concerns  or  inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE  PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT  FINANCIAL  ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO  WARRANTY  OR  LIABILITY  ASSUMED

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.AnalystsReview.com

SOURCE Analysts Review